The move reflects a growing interest in the PD-1 and VEGF pathways in the cancer space. Earlier this year, Summit ...

The real estate firm behind the tallest building in Queens held a "topping out" ceremony Wednesday morning to celebrate ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Conversations focused on Innovative Whole Health Strategies: Where Care, Science, AI And Economics Converge Judy Faulkner, Stéphane Bancel and Annie Lamont to Speak at 2024 Summit ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

GOTHENBURG, SWEDEN / ACCESSWIRE / November 13, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November ...

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American ... Serina presented a case study at the 14th Annual Injectables Summit in Boston, MA, detailing the ...

On Monday, Summit Therapeutics Inc (SMMT) stock saw a modest uptick, ending the day at $21.77 which represents a slight increase of $0.36 or 1.68% from the prior close of $21.41. The stock opened at ...

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, today highlighted a key opinion leader presen ...